Using contrast-enhanced ultrasound to evaluate pancreatic lesions
Characterization of Pancreatic Lesions Using Dynamic Contrast-enhanced Ultrasound
NA · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT05977777
This study is testing a new ultrasound technique to see if it can help doctors tell the difference between cancerous and non-cancerous growths in the pancreas for better treatment options.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Fondazione Policlinico Universitario Agostino Gemelli IRCCS (other) |
| Locations | 1 site (Roma) |
| Trial ID | NCT05977777 on ClinicalTrials.gov |
What this trial studies
This study aims to characterize pancreatic lesions using dynamic contrast-enhanced ultrasound (DCEUS), a technique that allows for objective assessment of vascular enhancement in pancreatic neoplastic diseases. Given the high mortality rate associated with pancreatic cancer and the limitations of current imaging modalities, this research seeks to improve diagnostic accuracy and treatment strategies. Participants will undergo DCEUS to better differentiate between malignant and benign pancreatic lesions, potentially leading to more effective management of the disease.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with at least one pancreatic lesion visible on B-mode ultrasound.
Not a fit: Patients who are under 18 years of age, have known allergies to ultrasound contrast agents, or have conditions such as heart failure, pregnancy, or lactation may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the diagnostic accuracy for pancreatic cancer, leading to earlier detection and improved treatment outcomes for patients.
How similar studies have performed: While there is limited data on the use of DCEUS specifically for pancreatic lesions, advancements in imaging technology suggest potential for success in this area.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria are: * written informed consent * at least 18 years of age * at least one pancreatic lesion visible in B-mode US and investigated trough CEUS Exclusion criteria: * less than 18 years of age * absence of informed consent * knowm allergy to ultrasound contrast agent * hearth failure * pregnancy * lactation
Where this trial is running
Roma
- Fondazione Policlinico Gemelli IRCCS — Roma, Italy (RECRUITING)
Study contacts
- Study coordinator: Maria Assunta Zocco
- Email: mariaassunta.zocco@policlinicogemelli.it
- Phone: 00393470597805
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Pancreatic Cancer